Research Paper Volume 11, Issue 20 pp 8745—8759

Figure 1. lncRNA GAS5 was downregulated in DN and negatively associated with the severity of DN-related complications. (A) Expression levels of GAS5 was detected by qPCR in T2D with or without DN (n=30); (B) Expression levels of GAS5 was detected by qPCR in DN with microalbuminuria or with macroalbuminuria (microalbuminuria group=13, macroalbuminuria group=17); (C) Based on the average value of eGFR, expression levels of GAS5 were detected in low or high eGFR (low eGFR group=12, high eGFR group=18); (D) Based on the average value of albumin/creatinine, expression levels of GAS5 were detected in low or high albumin/creatinine (low albumin/creatinine=15, high albumin/creatinine=15); (E) Expression levels of GAS5 were detected by qPCR in MCs treated with high glucose and compared with those in MC treated with normal glucose after 36 h treatment; (F) Expression levels of GAS5 were detected by qPCR in MCs treated by high glucose for 0, 4, 8 day; (G) H&E staining results of the DN rat model and negative control. Results indicated that the epithelium cells of tubule were edematous. Glomerular mesangial proliferation is shown in DN (N=8); (H) Blood glucose was detected in the DN rat model and negative control (N=8); (I, J) fibrosis-related proteins (FN, Col-4, and TGF-β) were measured in the DN rat model and negative control (N=8); (K) Urinary albumin excretion rate was measured in the DN rat model and negative control (N=8); (L) Expression level of GAS5 was detected in the DN rat model and negative control (M) The expression level of GAS5 was detected by qPCR in the DN rate model and negative control. Results showed that the expression level of GAS5 was downregulated in the DN rat model (N=8). Three independent experiments were performed. *P < 0.05, **P < 0.01.